Barclays PLC Pax Medica, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023
BUY
$1.4 - $53.55 $140 - $5,355
100 New
100 $0

About PaxMedica, Inc.

PXMD Quotes by TradingView
  • Ticker PXMD
  • Exchange
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,779,500
  • Market Cap $707K
  • Description
  • PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, my...
More about PXMD
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email